Douglas Riddle, MD
Family Medicine · Edmond, OKNPI 1659310928
Payments from drug & device makers
Across 311 payments — averaging $13.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$901
- Pfizer$675
- GSK$411
- Novo Nordisk$283
- Astellas Pharma US Inc$277
- AstraZeneca$242
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,08999%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $901 |
| Pfizer | 49 | $675 |
| GSK | 40 | $411 |
| Novo Nordisk | 25 | $283 |
| Astellas Pharma US Inc | 18 | $277 |
| AstraZeneca | 17 | $242 |
| Johnson & Johnson | 25 | $176 |
| Merck | 20 | $167 |
| Lilly USA, LLC | 8 | $131 |
| Amarin Pharma, Inc. | 8 | $104 |
| Nevro Corp. | 2 | $101 |
| Amgen | 7 | $98 |
| Dexcom, Inc. | 5 | $77 |
| Novartis | 4 | $72 |
| Abbott | 3 | $57 |
| Boehringer Ingelheim | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $37 |
| Ironwood Pharmaceuticals, Inc | 2 | $27 |
| Pulmonx Corporation | 1 | $26 |
| Nalpropion Pharmaceuticals LLC | 2 | $24 |
| Biohaven Pharmaceuticals, Inc. | 2 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Medicure Pharma Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Optinose US, Inc. | 1 | $13 |
How this compares
$4,124 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 186 | $217,277 |
| OzempicSemaglutide | 67 | $87,086 |
| MounjaroTirzepatide | 59 | $66,796 |
| EliquisApixaban | 40 | $62,291 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $26,544 |
| XareltoRivaroxaban | 30 | $22,539 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $17,911 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $16,426 |
| FarxigaDapagliflozin Propanediol | 19 | $15,802 |
| LinzessLinaclotide | 19 | $13,884 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $13,316 |
| LivaloPitavastatin Calcium | 13 | $11,363 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $7,240 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,155 |
| Rosuvastatin Calcium | 206 | $5,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $45 | $217,277186 claims |
| Novo NordiskOzempic | $283 | $87,08667 claims |
| Lilly USA, LLCMounjaro | $131 | $66,79659 claims |
| PfizerEliquis | $675 | $62,29140 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $411 | $55,69590 claims |
| Johnson & JohnsonXarelto | $176 | $22,53930 claims |
| AstraZenecaFarxiga | $242 | $15,80219 claims |
| AbbVieLinzess | $901 | $13,88419 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $14 | $11,36313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Edmond
- Stanley ShadidEdmond$363K
- Susan DimickEdmond$256K
- Charles WoodwardEdmond$15K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.